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Neuronal damage after an acute brain 
insult, such as stroke and brain trauma, 
remains a major cause of morbidity and 
mortality worldwide and affects millions 
of lives every year. However, effective 
treatments remain lacking, which makes 
the identification of new therapeutic tar-
gets a matter of great importance. In this 
issue of Cell, Tu et al. identify DAPK1 
(death-associated protein kinase 1) as a 
key component of a neuronal death sig-
naling cascade downstream of NMDA 
(N-methyl-D-aspartate) glutamate recep-
tors that mediates excitotoxic/ischemic 
brain damage after stroke. They provide 
convincing evidence that DAPK1 may be 
a target for the development of effective 
neuroprotectants.
The NMDA receptor (NMDAR) is a 
subtype of calcium-permeable ionotro-
pic glutamate receptors that mediate 
fast synaptic transmission at the vast 
majority of excitatory synapses in the 
mammalian brain. Molecular cloning has 
thus far identified a number of NMDAR 
subunits classified into three subfami-
lies: NR1, NR2 (A–D), and NR3 (A and 
B). Most native NMDARs are tetrameric 
complexes consisting of two essential 
NR1 subunits and one or more regulatory 
NR2 subunits, most commonly NR2A 
and/or NR2B. NMDARs have important 
roles in synaptic physiology, includ-
ing synaptic plasticity. However, during 
pathological conditions such as after 
stroke and brain trauma, NMDARs are 
excessively activated by an uncontrolled 
increase in the concentration of extra-
cellular glutamate, resulting in increased 
Ca2+ influx and neuronal death (Lipton 
and Rosenberg, 1994). Recent studies 
(Hardingham et al., 2002; Liu et al., 2007) 
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Excessive activation of NMDA glutamate receptors contributes to neuronal death after stroke. In 
this issue, Tu et al. (2010) demonstrate that ischemic injury promotes the association of death-
associated protein kinase 1 with the NMDA receptor, thereby potentiating its activity, and show 
that disrupting this association reduces damage to the brain.
Figure 1. Countering Excitoxicity Mediated by the NMDA Receptor
(A) Under basal synaptic transmission, activation of synaptic (predominantly NR2A-containing) NMDA receptors (NMDAR) stimulates a neuronal survival signal-
ing complex (SSC), promoting neuronal survival (Hardingham et al., 2002; Liu et al., 2007).
(B) After stroke, the increased extracellular concentration of glutamate causes overflow of synaptic glutamate and the excitotoxic activation of extrasynaptic 
(predominantly NR2B-containing) NMDARs (Hardingham et al., 2002; Liu et al., 2007). The increase in Ca2+ influx through NR2B-containing NMDARs activates 
DAPK and sequentially promotes the active DAPK (aDAPK) to bind and phosphorylated NR2B (Tu et al., 2010). aDAPK recruitment then promotes the activation 
of a neuronal death signaling complex (DSC) that in turn shuts off the synaptic SSC activity (Hardingham et al., 2002), and promotes neuronal death.
(C) Application of NR2B-derived interference peptide (NR2BCT) inhibits the binding of aDAPK to NR2B and blocks phosphorylation of the receptor. Loss of the 
interaction between aDAPK and NR2B reduces activation of DSC and because of this averts the excitotoxic neuronal damage induced by stroke (Tu et al., 2010).
For simplicity, NR2B-containing synaptic and NR2A-containing extrasynaptic NMDA receptors are omitted from the figure.
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suggest that a preferential activation of 
synaptically localized NMDARs, which 
predominantly contain NR2A (Tovar and 
Westbrook, 2002; Liu et al., 2007), have 
a prosurvival role via activation of a neu-
ronal survival signaling complex that is 
coupled to these receptors. In contrast, 
activation of extrasynaptic NMDARs, 
which predominantly contain NR2B 
(Tovar and Westbrook, 2002; Liu et al., 
2007), may have a cell death-inducing 
role through stimulation of a neuronal 
death signaling complex (Figure 1).
Despite promise in preclinical animal 
models, clinical trials for direct antago-
nism of the NMDAR as a stroke thera-
peutic have been disappointing, perhaps 
because of interference with physiologi-
cal NMDAR function or a narrow thera-
peutic window. However, emerging evi-
dence suggests that these problems 
might be circumvented by selectively 
targeting molecular components of the 
death signaling cascade downstream 
of NR2B-containing NMDARs (Aarts et 
al., 2002; Taghibiglou et al., 2009). In this 
issue, Tu and colleagues used coimmu-
noprecipitation with NR2B-spcific anti-
bodies and mass spectrometry to iden-
tify new signaling molecules engaged in 
the neuronal death cascade. They dis-
cover that after stroke insult, the NMDAR 
complex interacts with DAPK1, a mem-
ber of a serine/threonine kinase family 
well known for their roles in cell death 
(Bialik and Kimchi, 2006).
The authors demonstrate that DAPK1 
directly interacts with the NMDAR via an 
interaction in the carboxyl tail region of 
the NR2B subunit. By defining the exact 
binding domain of DAPK1 in NR2B, the 
authors are able to design an interference 
peptide (NR2BCT; Figure 1) that effec-
tively disrupts the interaction of DAPK1 
with NMDARs during stroke. Using a cell 
line expression system, the authors find 
that only constitutively active DAPK1 is 
able to interact with NR2B and potenti-
ate currents gated through the NR2B- 
(but not NR2A-) containing NMDARs. 
Importantly, the interference peptide 
effectively blocks both the association 
of DAPK1 with NR2B and the poten-
tiation of NMDAR function. The authors 
then identified a single serine residue 
(Ser-1303) within the DAPK1 binding 
domain of NR2B that shows increased 
phosphorylation with DAPK1 activation. 
Mutation of this site eliminates the abil-
ity of active DAPK1 to potentiate NMDAR 
currents, suggesting that the phosphory-
lation is critical to the DAPK1 response. 
It is worth noting that the authors do not 
show direct evidence of DAPK1 phos-
phorylation of Ser-1303; thus, the initial 
phosphorylation event may be due to 
other kinases downstream of DAPK1.
These findings suggest that the 
DAPK1-NR2B interaction may have 
a role in neuronal injury after excito-
toxic and ischemic insults. Therefore, 
to examine whether DAPK1 activation 
plays a causative role in neuronal dam-
age, the authors generated a DAPK1 
knockout mice. Mice lacking DAPK1 
are viable, and basal synaptic signaling 
and function appear to be unaffected. 
Using neuronal cultures deprived of 
oxygen and glucose to activate DAPK1, 
the authors noted an increase in cur-
rents and calcium transients gated 
through extrasynaptic (but not syn-
aptic) NMDARs. This increase is not 
observed in neurons from mice lack-
ing DAPK1, demonstrating that the 
potentiation by DAPK1 is specific to 
NR2B-containing NMDARs. In both 
the culture model and models of stroke 
in vivo, neuronal death is reduced in 
the absence of DAPK1. These results 
clearly demonstrate a critical role of 
DAPK1 in mediating neuronal damage 
after ischemia.
To demonstrate whether the associa-
tion of DAPK1 with NR2B is responsible 
for the ischemic neuronal damage, the 
authors made a variant of the NR2BCT 
peptide that is membrane permeable. 
Remarkably, systemic injection of 
NR2BCT specifically blocks the asso-
ciation with and phosphorylation of the 
NR2B subunit by DAPK1 after transient 
focal ischemia, and markedly reduces 
infarct size compared to animals treated 
with a control peptide (Figure 1C). It is 
important to note that the neuroprotec-
tive effects of NR2BCT are effective even 
when given 60 min after stroke and are 
not associated with a general alteration 
in the activity and amount of DAPK1 in 
these treated animals. These results 
not only provide evidence that the for-
mation of the DAPK1-NR2B complex is 
an essential step in cell death signal-
ing cascades downstream of NMDARs, 
but also suggest that agents that dis-
rupt the association between DAPK1 
and NR2B may represent a new class 
of neuroprotective therapeutics against 
stroke (Figure 1).
There are several important ques-
tions arising from this study for future 
research. For instance, how is active 
DAPK1 recruited to the NR2B subunit? 
One possibility proposed by the authors 
is that DAPK1 may be activated by a cal-
cinurin-mediated dephosphorylation of 
the kinase after excessive activation of 
the receptors that contain NR2B. Hypo-
thetically, the resulting conformational 
change may then lead to the exposure 
of the NR2B binding region, presumably 
within the enzymatic region of DAPK1. It is 
interesting to note that Ser-1303 and the 
surrounding residues of NR2B required 
for DAPK1 binding have also previously 
been identified as a binding site for 
CaMKII, a calcium/calmodulin depen-
dent kinase (Strack et al., 2000). Under 
basal conditions, CaMKII is bound to the 
NR2B subunit at the region surrounding 
Ser-1303 in its dephosphorylated state. 
However upon calcium influx, Ser-1303 
is phosphorylated, causing CaMKII 
to slowly dissociate from the site. It is 
important for future work to clarify how 
CaMKII-mediated phosphorylation and 
binding of NR2B affects DAPK1 associa-
tion with and phosphorylation of NR2B. 
It is worth noting that Tu et al. do not 
observe a change in the quantity of CaM-
KII associated with the NMDA receptor in 
response to stroke or following the appli-
cation of NR2BCT. However, the activated 
CaMKII may remain within the NR2B 
complex via an alternative NR2B site as 
proposed by a previous study (Bayer et 
al., 2001).
Future research is also important to 
determine how DAPK1 binding to NR2B 
induces cell death. The authors pres-
ent data suggesting that the binding is 
upstream of c-Jun N-terminal protein 
kinase (JNK) activation, an important 
step previously implicated in induction of 
neuronal death, but whether this is a con-
sequence of DAPK1-dependent poten-
tiation of NR2B-containing NMDARs or 
direct activation of the neuronal death 
signaling cascade is unclear. It is worth 
noting that specific antagonists of NR2B-
containing NMDAR have shown little 
promise as a poststroke therapeutic, 
suggesting that changes in channel con-
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ductance may not be critical in neuronal 
death at a later stage of stroke (Liu et al., 
2007). Furthermore, a number of studies 
have identified other signaling compo-
nents downstream of NR2B required for 
excitotoxic/ischemia induced neuronal 
death, such as neuronal nitric oxide syn-
thase (Aarts et al., 2002) and SREPB1 
(Taghibiglou et al., 2009), and it will be 
important to identify how these tie into 
the findings of Tu et al.
Finally, it will also be interesting to 
explore the role of DAPK1 under physi-
ological conditions. Its strong neuronal 
expression and localization in the post-
synapse suggest a role in synaptic func-
tion yet to be discovered. Either way, the 
findings of Tu et al., along with several 
other studies (Aarts et al., 2002; Taghibi-
glou et al., 2009), support the con-
cept that targeting cell death signaling 
downstream of NMDARs is an effective 
neuroprotective strategy. In this regard, 
we very much share the hope with the 
authors that their discoveries might lead 
to new effective treatments for stroke.
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The separation of germ cells from the 
soma potentiates the propagation of a 
species that lacks senescence, because 
new mechanisms emerge to preserve 
youthfulness in the specialized germ cells 
(Weisman, 1892). In contrast, somatic 
cells age, at least in part, because they 
lack these mechanisms. The budding 
yeast provides a conceptual analog of 
the germ cell/somatic cell demarcation, 
because cells divide asymmetrically to 
give a young daughter cell that arises 
from the bud (the germ cell analog) and 
a mother cell that grows older with each 
budding event (the somatic cell ana-
log). Studies by the Nystrom lab have 
shown that damaged protein aggregates 
accumulate in aging mother cells, but 
not in their daughters (Aguilaniu et al., 
2003). Now, in this issue, Liu et al. (2010) 
uncover an exciting new mechanistic 
basis for this asymmetry. They show 
that these damaged protein aggregates 
undergo retrograde transport along actin 
cables out of the growing bud and into 
the mother cell (Figure 1).
The path leading to this discovery was 
based on this group’s earlier finding that 
the asymmetric segregation of damaged 
proteins between mother and daughter 
cells required the anti-aging gene SIR2. 
This gene encodes an NAD-dependent 
deacetylase that retards aging in organ-
isms ranging from yeast to mammals 
(Finkel et al., 2009). In their new work, Liu 
et al. (2010) looked for new SIR2 functions 
using synthetic gene arrays (Tong et al., 
2004) to identify genes that are required 
for survival of sir2 yeast mutants. Not 
surprisingly, one major category of 
genes was involved in the maintenance 
of chromatin. Less expected was the 
large number of genes involved in actin-
related cellular processes, including 
genes that encode components of the 
polarisome (Moseley and Goode, 2006). 
The polarisome is a structure located at 
the distal end of the yeast bud that forms 
a focal point for polymerization of actin 
monomers into cables that extend from 
the bud tip to the mother cell (Figure 
1). These actin cables transport cargo 
from mother to daughter cell to support 
bud growth. This genetic association 
between a gene encoding a polarisome 
component and SIR2 is specific as no 
such interactions were observed for the 
yeast SIR2 paralogue, HST2.
The authors identify a likely mechanis-
tic link between Sir2p and the polarisome 
by analyzing actin itself. In sir2 mutant 
strains, there is a substantial amount of 
unfolded actin monomers. In addition, 
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Propagation of a species requires periodic cell renewal to avoid clonal senescence. Liu et al. (2010) 
now describe a new mechanism of cell renewal in budding yeast, in which damaged protein aggre-
gates are transported out of the daughter buds along actin cables to preserve youthfulness.
